Nanotechnology Now - Press Release: Rodman & Renshaw Global Healthcare Conference 2007 Presenter Profiles

Home > Press > Rodman & Renshaw Global Healthcare Conference 2007 Presenter Profiles

Abstract:
Rodman & Renshaw Global Healthcare Conference 2007 takes place May 14 - 15, 2007 at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. For in-depth information about the event, visit http://www.rodmanandrenshaw.com/Conferences.asp?CID=conf20 .

Rodman & Renshaw Global Healthcare Conference 2007 Presenter Profiles

MONTE CARLO, Monaco | Posted on May 11th, 2007

Listed below are Rodman & Renshaw Global Healthcare Conference 2007 presenter profiles. Business Wire is the official news wire for the Rodman & Renshaw Global Healthcare Conference. Breaking news releases are available at Tradeshownews.com, Business Wire's trade show, conference, and event news resource.
Company: Accentia Biopharmaceuticals, Inc.
Ticker Symbol & Exchange: NASDAQ: ABPI
Investor Relations Contact: Adam S. Holdsworth, 212-825-3210
Web: http://www.accentia.net
Date of Presentation: 5/14/2007

Accentia Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of late-stage "disruptive" clinical products, especially for already-approved drugs in new formulations and/or new indications that are patent-protected and which represent new therapeutics with greater clinical and economic value. Accentia has a pipeline of products in late-stage clinical development. The company's lead respiratory product candidate is SinuNase™, which is under clinical development to treat chronic sinusitis (rhinosinusitis). SinuNase is a novel application and formulation of a known anti-fungal exclusively licensed from the Mayo Foundation for Medical Education and Research. The product has been Fast Tracked by the FDA and the Company has commenced a Phase 3 clinical trial. The Company's other lead product is BiovaxID™, a patient-specific anti-cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma. BiovaxID, which is being developed by Accentia's subsidiary, Biovest International, Inc. (OTCBB: BVTI), is currently in a Fast-Tracked Phase 3 clinical trial. Through Biovest, the Company also manufactures AutovaxID™, an FDA approved commercial-stage automated cell-manufacturing device that enables the cost-effective and scalable production of proteins and other cell-based products. Accentia is also proposing to enter a Phase 3 clinical trial for Multiple Sclerosis using Revimmune™, which uses an approved drug in an exclusively licensed method of therapy to "reboot" a patient's immune system. Revimmune was developed at the Johns Hopkins School of Medicine for the elimination of autoimmunity, and Accentia has acquired the exclusive worldwide rights for all autoimmune diseases. For further information, please visit http://www.accentia.net .

Company: Accera, Inc.
Investor Relations Contact: Meghan Feeks, Richard Lewis Communications, Inc., 212.827.0020
Web: http://www.accerapharma.com
Date of Presentation: Tuesday, May 15, 11:30 a.m.
Accera, Inc. is a private biopharmaceutical company focused on the discovery and development of novel therapeutics for neurodegenerative diseases. Based on a deep understanding of the neuronal metabolism defects commonly observed in CNS diseases, Accera's proprietary neuron energetics technology platform is being used to develop drugs in multiple indications including Alzheimer's disease, age-associated memory impairment, Parkinson's disease, and canine cognitive dysfunction. Through its own small molecule discovery program, in-licensing, and the acquisition of clinical compounds with demonstrated safety and efficacy, Accera continues to build a strong and diversified product pipeline.

Company:

Altegen, Inc
Investor Relations Contact: Martin Atterby, 49 172 4583865 / 49 172 4583866
Web: http://www.altegen.com
Date of Presentation: 15.05.2007

Altegen has developed "samfor" blood tests for the pre-symptomatic / symptomatic diagnosis of major human diseases. "Samforad" detects expression of an AD-specific Beta-amyloid precursor protein "ALZAS" (protein and RNA) and an anti-ALZAS auto-antibody. Anti-ALZAS/ALZAS blood levels enable determination of staging of AD and probably of the efficacy of therapeutic treatments. Launch for Samforad is September 2007. Anti-ALZAS vaccine clinical trial phases I/II starts February 2008. "Samformad" screens human blood for BSE by detecting "Prionins." Ready-for-use-PrPSc is produced in minutes by converting in vitro (in test tubes) all species of native or recombinant PrP using prionins. European patents have been granted.

Company: Alteon Inc
Ticker Symbol & Exchange: ALT
Investor Relations Contact: Noah Berkowitz, 201 818 5877
Web: http://www.alteon.com
Date of Presentation: 14-May-07
Alteon is a product-based biopharmaceutical company engaged in the development of drugs to treat and prevent cardiovascular diseases, particularly among patients with diabetes.

ALT-2074, is a glutathione peroxidase mimetic shown to protect myocardium in preclinical models of heart attack. The drug is in clinical development for reducing the morbidity and mortality following MI, in patients with diabetes and a variant of an high risk biomarker called haptoglobin. Alagebrium chloride is an Advanced Glycation End-product Crosslink Breaker being developed for diastolic heart failure and nephropathy. These diseases represent a rapidly growing market of unmet medical need, particularly common among diabetic patients.

Company: Aus Bio Limited
Investor Relations Contact: Dr Peter Jenkins - Executive Director, (61) 411 88 46 42
Web: http://www.ausbio.com.au
Date of Presentation: 14th May, 2007 0820 hrs. - Zephyr Salon
AusBio is a medicinal biochemistry company. By linking the discipline of molecular medicine, new drug candidates have been created, for disease states, which are large and require new therapeutics. The Company's principal scientists have a proven track record of international commercial success following innovative R & D. Principal projects include diabetes mellitus, chronic wound healing, chronic hepatitis B & C, immune modulators and acute/chronic respiratory conditions. Lead candidate selection and Proof of Concept has occurred with the diabetes and wound healing projects, the latter now entering a Phase II study. All I.P. created in house and owned outright.

Company: Avalon Pharmaceuticals, Inc.
Ticker Symbol & Exchange: NASDAQ: AVRX
Investor Relations Contact: David M. Muth, 301-556-9900 (U.S.)
Web: http://Avalonrx.com
Date of Presentation: Monday, May 14, at 3:15 p.m. CEST (Central European Summer Time), 9:15 a.m. EDT (Eastern Daylight Time).

Avalon Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of potential first-in-class cancer therapeutics. Avalon has a lead product in Phase I clinical development (AVN944), preclinical programs to develop inhibitors for the Beta-catenin and Aurora pathways, discovery programs for Survivin and Myc pathway inhibitors, and value generating partnerships with Merck, MedImmune, Medarex, and Novartis. By utilizing AvalonRx® our platform technology, based upon the proprietary use of large-scale gene expressions, we are uniquely positioned to develop therapeutics focused on pathways that have historically been characterized as "undruggable." Avalon was established in 1999 and is headquartered in Germantown, Maryland.

Company: Axcan Pharma Inc.
Ticker Symbol & Exchange: NASDAQ Global Market: AXCA / Toronto Stock Exchange: AXP
Investor Relations Contact: Isabelle Adjahi, 450-467-2600 ext. 2000 (Canada)
Web: http://www.axcan.com
Date of Presentation: 5/15/2007
Axcan is a leading multinational specialty pharmaceutical company focused on gastroenterology. The company develops and markets a broad line of prescription products to treat a range of gastrointestinal diseases and disorders such as inflammatory bowel disease, irritable bowel syndrome, cholestatic liver diseases and complications related to pancreatic insufficiency. Axcan's products are marketed by its own specialized sales forces in North America and Europe.

Company: BioLineRx Ltd.
Ticker Symbol & Exchange: Tel Aviv: BLRX
Investor Relations Contact: Yuri Shoshan, VP Finance and Corporate Development, 972-2-548-9100
Email:
Web: http://www.biolinerx.com
Date of Presentation: May 14, 2007, 4:40 PM ET
BioLineRx is Israel's leading drug development company. Partnering with researchers, universities and biotech companies, BioLineRx advances projects from early stage discovery and lead generation to advanced clinical trials, regulatory approval and marketing. The Company was founded in 2003 by leaders in the Israeli life science arena including Teva Pharmaceuticals Ltd., venture capital firms Giza, Pitango and Hadasit, the technology transfer company of Hadassah hospital.

The Company's leading programs are for the treatment of schizophrenia and damaged heart tissue post-myocardial infarction. Additional products under development include compounds for the treatment of cancer and CNS, cardiovascular, metabolic, infectious and autoimmune diseases.

Company: Bionovo, Inc
Ticker Symbol & Exchange: BNVI
Investor Relations Contact: Jim Stapleton, 510.601.2000
Web: http://www.bionovo.com
Date of Presentation: Mon. May 14th 8:40am
Bionovo (BNVI) is a publicly traded pharmaceutical company focused on discovering and developing drugs for women's health and cancer. Bionovo is a leader in systems-biology integration with candidates designed to address specific targets associated with the regulation of pathological conditions. The company is working simultaneously on two distinct discovery approaches, one focusing on pro-apoptotic agents for cancer and a second, in the area of selective estrogen receptor modulators (SERMS) to treat severe menopausal symptoms. Both approaches are highly selective to yield products that will effectively and safely address these areas of high unmet need. The company's clinical development strategy leverages relationships with key faculty at leading research institutions to conduct trials with recognized opinion leaders.

Company: BioSante Pharmaceuticals, Inc.
Ticker Symbol & Exchange: Amex: BPA
Investor Relations Contact: Phillip Donenberg, 847-478-0500 ext 101
Web: http://www.biosantepharma.com
Date of Presentation: 14-May-07
BioSante is developing a pipeline of hormone therapy products to treat both men and women. BioSante's lead products include Elestrin™ (estradiol gel), developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and LibiGel® (transdermal testosterone gel) in Phase III development for the treatment of female sexual dysfunction (FSD). The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including hepatitis B, avian flu and biodefense vaccines for toxins such as anthrax, as well as a system for delivering drugs via alternative routes of administration.

Company: DOV Pharmaceutical, Inc.
Ticker Symbol & Exchange: DOVP.PK (Pink Sheets)
Investor Relations Contact: Matthew Moore, 732-907-3667
Web: http://www.dovpharm.com
Date of Presentation: Tuesday, May 15, 2007
DOV is a biopharmaceutical company focused on the discovery, acquisition and development of novel drug candidates for CNS disorders. We have active drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (entering Phase II for depression), DOV 102,677 (Phase I for alcohol abuse) and an active preclinical discovery program in reuptake inhibitors and GABA modulators. We have entered into a sublicensing agreement with Neurocrine Biosciences, for indiplon for the treatment of insomnia and with XTL Development, for bicifadine for the treatment of pain. We are seeking a partner for DOV diltiazem for the treatment of angina and hypertension.

Company: DURECT Corporation
Ticker Symbol & Exchange: DRRX; Nasdaq
Investor Relations Contact: Matthew J. Hogan, 408-777-4936
Web: http://www.durect.com
Date of Presentation: 14-May-07
DURECT Corporation is an emerging specialty pharmaceutical company developing pharmaceutical systems based on its proprietary drug delivery platform technologies. The Company currently has a number of late-stage pharmaceutical products in development addressing large markets in pain management, with a number of research programs underway targeting chronic disease and other therapeutic areas. For more information, please visit http://www.durect.com .

Company: EntreMed, Inc.
Ticker Symbol & Exchange: ENMD
Investor Relations Contact: Ginny Dunn, 240-864-2643
Web: http://www.entremed.com
Date of Presentation: Monday, May 14, 2007
EntreMed, Inc. is a clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells directly and the blood vessels that nourish them.

EntreMed's goal is to develop and commercialize therapeutics based on the Company's scientific expertise in angiogenesis, cell cycle regulation and inflammation -- processes vital to the progression of cancer and other diseases. The Company's three clinical product candidates are based on these mechanisms. The Company's expertise has also led to the identification of new molecules, including new chemical entities derived from 2ME2, as well as new chemical entities associated with multi-kinase inhibition and HDAC inhibition, important targets in the treatment of oncology.

Company: Evotec AG
Ticker Symbol & Exchange: FSE: EVT
Investor Relations Contact: Anne Hennecke, 49-40-56081-286
Web:
Date of Presentation: 14 May 2007, 05.20 pm
Evotec is a leader in the discovery and development of novel small molecule drugs.

In proprietary projects, Evotec specialises in finding new treatments for diseases of the central nervous system. Evotec has three programmes in clinical development: EVT 201 (GABAA modulator) for the treatment of insomnia, EVT 101 (NMDA NR2B subtype antagonist) for the treatment of Alzheimer's disease/pain and EVT 302 (MAO-B inhibitor) in development for smoking cessation.

In contract research, Evotec has established itself as the partner of choice for pharmaceutical and biotechnology companies worldwide. The Company provides innovative and often integrated solutions from drug target to clinic through an unmatched range of capabilities, including early stage assay development/screening through to medicinal chemistry and drug manufacturing.

Company: GammaCan International Inc.
Ticker Symbol & Exchange: OTC BB: GCAN
Investor Relations Contact: Yaron Cherny, 972 3 738 2616 / 972 54 399 1313
Web: http://www.GammaCan.com
Date of Presentation: May 14th
GammaCan (OTCBB: GCAN) develops immunotherapies to treat cancer. VitiGam™ is GammaCan's lead program in development for the treatment of stage III and stage IV melanoma. Based on having demonstrated potent anti-melanoma activity in animal models, VitiGam™ is expected to enter Phase I/II trials under an U.S. IND in 2008. VitGam™ is an IgG-based product manufactured from plasma of donors with vitiligo, a benign skin condition. GammaCan owns U.S. patents covering uses of IgG to treat cancer and vitiligo-derived IgG (VitiGam™) to treat melanoma. GammaCan has additional pending patent applications covering IgG-based therapies. GammaCan is located in Israel and the U.S.

Company: Genetic Immunity
Investor Relations Contact: Dr. Julianna Lisziewicz, 36-30-550-5596
Web: http://www.geneticimmunity.com
Date of Presentation: May 14, from 12:15 to 12:35 PM Zephyr Salon
Genetic Immunity, a US-Hungarian biopharmaceutical enterprise, is a leader in the development of proprietary DNA nanoparticle-based topical cellular vaccines. The lead product, DermaVir Patch for the treatment of HIV/AIDS, has been demonstrated safe and effective in NIH sponsored primate studies. A Phase I clinical trial demonstrated safety and long-lived cellular immunogenicity in HIV-infected individuals. NIH and Karolinska Institute sponsored Phase II trials are underway in the US and EU. Product pipeline based on the Company's patented platform technology is under development through the Vaccine Therapy Cluster (www.vaccinetherapy.eu).

Company: GENFIT
Ticker Symbol & Exchange: ALGFT
Investor Relations Contact: Guillaume LOHR, 33 (0)6 07 34 14 77,
Date of Presentation: 5/14/2007
Genfit is an innovative biopharmaceutical company, enabling and developing 'first in class' or 'best to market' medicines for the prevention and treatment of cardiometabolic disease, the leading cause of mortality in the world.

Located in Lille, (France) and Cambridge (MA, USA), Genfit scientific foundations are based on the renown expertise of Prof. Jean-Charles Fruchart and Prof Bart Staels, and has been managed from inception by Mr Jean-Francois Mouney, combining many years of experience in both business and science. Genfit nurtures innovative drug research in an advanced scientific environment, with clinical output as the key permanent objective.

Genfit's mission is to discover and develop innovative new chemical entities targeting metabolic diseases, inflammatory disorders, and more generally cardiometabolic risk factors (dyslipidemia, atherosclerosis, diabetes, obesity, hypertension, neurodegenerative diseases…): Our aim is to improve the care of patients by researching and developing today, better and safer treatments for the future either based on new therapeutic targets (with a strong focus on nuclear receptors), or on a "multimodal drug discovery approach", targeting several indications simultaneously.

With a unique partnering track-record, Genfit recognizes that pharmaceutical R&D needs multiple types of expertise and resources, and our company culture values alliances with leading international pharmaceutical groups, at different stages on the drug discovery and development value chain.

Company: Glycadia Pharmaceuticals
Investor Relations Contact: Perry M. Cohen, (215) 557-8021
Web: http://Glycadia.com
Date of Presentation: 5/14/2007
Glycadia is developing drugs to treat kidney, eye and cardiovascular complications of diabetes. These innovative and proprietary therapies target upstream diabetes-specific abnormalities contributory to these disorders that result from diabetes.

The prevalence of diabetes and its complications has reached epidemic proportions. There are no drugs available that directly target diabetes-specific abnormalities underlying the microvascular and macrovascular diseases associated with diabetes.

Glycadia's lead candidate, GLY-230, an orally active small molecule, is in clinical trials for diabetic nephropathy. Submission of Phase 2b protocols is expected in the second half of 2007.

Company: Hollis-Eden Pharmaceuticals, Inc.
Ticker Symbol & Exchange: NASDAQ: HEPH
Investor Relations Contact: Scott A. Rieger, 858-587-9333
Web: http://www.holliseden.com
Date of Presentation: 15-May-07
Hollis-Eden Pharmaceuticals is the world leader in the development of a proprietary class of small molecule compounds that are metabolites or synthetic analogs of endogenous adrenal steroid hormones. The Company's clinical drug development candidates include HE3286, a next-generation compound being prepared for clinical trials in treating type 2 diabetes and potentially rheumatoid arthritis, and HE3235, selected for clinical development in cancer. In addition, Hollis-Eden has an active research program that is generating additional new clinical leads that are being further evaluated in preclinical models of a number of different diseases.

Company: Hunter-Fleming Ltd
Investor Relations Contact: Dr Michael Capaldi, 44 117 900 8265
Web: http://www.hunter-fleming.com
Date of Presentation: Tuesday 15th May
Dr Mike Capaldi, CEO of Hunter-Fleming Ltd. will be presenting the latest developments at the UK based biopharmaceutical company to the Rodman & Renshaw Global Healthcare Conference on 15th May 2007.

Hunter-Fleming specializes in the development of innovative medicines to treat inflammatory degenerative diseases. The Company's lead product is currently in phase II clinical development for Alzheimer's disease. Two further products are in phase I clinical development with a further compound series in lead optimization. A fifth product for asthma and other autoimmune diseases has been out-licensed to Trident Pharmaceuticals and will enter pre-clinical toxicology during 2007.

Company: ImClone Systems Incorporated
Ticker Symbol & Exchange: IMCL
Investor Relations Contact: Rebecca Gregory, 646-638-5058
Web: http://www.imclone.com
Date of Presentation: Monday, May 14, 2007
ImClone Systems Incorporated is committed to advancing oncology care by developing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. The Company's research and development programs include growth factor blockers and angiogenesis inhibitors. ImClone Systems' strategy is to continue to grow into a fully integrated biopharmaceutical company, taking its development programs from the research stage to clinical impact, and, ultimately, commercialization. ImClone Systems' headquarters and research operations are located in New York City, with clinical, regulatory, medical affairs, commercial, manufacturing, and additional administrative functions in Branchburg, New Jersey.

Company: Locus Pharmaceuticals, Inc.
Investor Relations Contact: Robert Dickey IV, 215-358-2006
Web: http://www.locuspharma.com
Date of Presentation: 15-May-07
Locus is a world leader in computational drug design. The Company's core technology is a fragment-based, computational approach, which Locus has combined with highly integrated medicinal chemistry, crystallography and biology capabilities to create a unique drug design and development platform. Locus is using its capabilities to develop its own compounds and has also entered into drug design/development collaborations with pharmaceutical partners. All of the Company's internal development programs emanate from its computational technology and are focused on oral drug therapies, principally in cancer and inflammation.

Company: LORUS THERAPEUTICS INC.
Ticker Symbol & Exchange: AMEX: LRP & TSX: LOR
Investor Relations Contact: Dr. Saeid Bababei, MBA., PhD., 416 798 1200 x 490
Web: http://www.lorusthera.com
Date of Presentation: 14-May-07
Lorus Therapeutics Inc. is a public Canadian biopharmaceutical Company engaged in the discovery and development of innovative, effective and safe products for the treatment of patients with cancer. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer.

Company: Maxygen, Inc.
Ticker Symbol & Exchange: Nasdaq: MAXY
Investor Relations Contact: Michele Boudreau, 650-279-2088
Web: http://www.maxygen.com
Date of Presentation: May 15, 11:10 am
Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs. We look for opportunities where our proprietary protein modification technologies can address significant therapeutic needs. Products developed by Maxygen now in clinical trials include a novel interferon-alpha for the treatment of hepatitis C virus (HCV) infection and a novel G-CSF for the treatment of neutropenia. Maxygen's approach may allow us to leverage the established development and regulatory paths of approved drugs. We believe this advantage translates to a greater chance of successfully bringing important new drugs to market.

Company: Medgenics, Inc.
Investor Relations Contact: Andrew Pearlman, Phyllis Bellin; 972-4-9588555, 972-54-2274827
Web: http://www.medgenics.com
Date of Presentation: May 15, 2007 , 3:15 pm, Atlantique Salon
Medgenics Inc. is a biopharmaceutical company developing a platform technology to provide sustained-action protein therapy for the treatment of a range of diseases, starting with anemia and hepatitis C. Medgenics has already shown proof-of-principle of the Biopump to deliver erythropoietin (EPO) in a clinical trial to anemic patients. The Company is developing two products based on its sustained-action Biopump technology: EPODURE producing EPO to treat anemia, and INFRADURE producing interferon-alpha to treat hepatitis C. For more information visit www.medgenics.com.

Company: MediGene AG
Ticker Symbol & Exchange: MDG
Investor Relations Contact: Dr. Michael Nettersheim, 49 - 89 - 85 65 - 2946
Web: http://www.medigene.com
Date of Presentation: May 15th 2007, 12:55 PM
MediGene AG is a publicly quoted (Frankfurt: Prime Standard: MDG) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company with a drug on the market. A second drug has been approved by the FDA. In addition, several drug candidates for the treatment of cancer and autoimmune diseases are currently in clinical development. MediGene also possesses innovative platform technologies.

Company: Medivation, Inc.
Ticker Symbol & Exchange: Nasdaq: MDVN
Investor Relations Contact : Patrick Machado, 415-543-3470 (IR) or Jani Bergan, 415-946-106 (PR)
Web: http://www.medivation.com
Date of Presentation: 14-May-07
Medivation, Inc. is a biopharmaceutical company with small molecule drugs in development to treat three large, unmet medical needs - Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. Dimebon™, the Company's lead product candidate, is currently being studied in clinical trials in patients with Alzheimer's disease and Huntington's disease. Six-month results from a Phase 2 trial in Alzheimer's disease demonstrated that Dimebon met all five efficacy endpoints with strong statistical significance compared with placebo.

Company: Morria Biopharmaceuticals Plc
Investor Relations Contact: Yuval Cohen, 44 (0)207 152 6341
Web: http://www.morria.com
Date of Presentation: May 14th

Morria Biopharmaceuticals Plc. is a UK based drug development company focused on novel anti-inflammatory drugs. Morria's lead products are first-in-class, non-steroidal, synthetic anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAID). The company has pre-clinical and clinical programs in dermatology, (contact dermatitis), respiratory (allergic rhinitis and cystic fibrosis) and gastro-intestinal inflammatory diseases (Inflammatory Bowel Disease). Morria is also engaged in Discovery Partnerships with Big Pharma in the fields of eyecare, ophthalmology and cardiovascular health.

Company: Neose Technologies, Inc.
Ticker Symbol & Exchange: Nasdaq GM: NTEC
Investor Relations Contact: Barbara Krauter, 215-315-9004
Web: http://www.neose.com
Date of Presentation: 15-May-07

Neose Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation therapeutic proteins that are competitive with best-in-class protein drugs currently on the market, on its own and through strategic partnerships. The lead candidates in its pipeline, NE-180 for use in the treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure and GlycoPEG-GCSF for chemotherapy-induced neutropenia, target markets with aggregate sales in excess of USD 15 billion. For more information, please visit www.neose.com.

Company: NicOx
Ticker Symbol & Exchange: Euronext: NICOX
Investor Relations Contact : Karl Hanks; 33 (0)4 97 24 53 43; and Irène Lalande; 33 (0)4 97 24 53 11;
Web: http://www.nicox.com
Date of Presentation: 15-May-07
NicOx is a product-driven biopharmaceutical company dedicated to the development of nitric oxide-donating drugs to meet unmet medical needs. NicOx is targeting the therapeutic areas of inflammatory and cardio-metabolic diseases. Resources are focused on two lead compounds, naproxcinod, in phase 3 development for the treatment of osteoarthritis, and NCX 4016, in phase 2 for type 2 diabetes. NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer Inc. and Merck and Co., Inc.

NicOx S.A. is headquartered in Sophia-Antipolis, France, and is a public company listed on the Eurolist of Euronext Paris (segment: Next Economy).

Company: NovaDel Pharma
Ticker Symbol & Exchange: AMEX: NVD
Investor Relations Contact: Susan H. Griffin, 908-782-3431 ext. 2423,
Web: http://www.novadel.com
Date of Presentation: Tuesday, May 15, 2007 @ 11:10a.m.
NovaDel Pharma Inc. is a specialty pharmaceutical company developing oral spray formulations of a broad range of marketed treatments. The Company's proprietary oral spray technology offers the patient the potential for (i) more rapid absorption of drugs to the bloodstream compared to conventional oral dosage forms; (ii) limited first pass liver metabolism; (iii) avoiding the need to swallow; (iv) allowing medication to be taken without water; (v) improved drug safety profile by reducing the required dosage; and (vi) improved patient convenience and compliance. NovaDel's most advanced candidates target nausea, insomnia, migraine headaches and disorders of the central nervous system (CNS).

Company: Novelos Therapeutics, Inc.
Ticker Symbol & Exchange: OTCBB: NVLT
Investor Relations Contact: Stephen Lichaw, 201-240-3200
Web: http://www.novelos.com
Date of Presentation: May 14, 2007, 9:45am
Novelos Therapeutics, Inc. is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. NOV-002, the lead compound currently in Phase 3 development for lung cancer under a SPA and Fast Track, acts together with chemotherapy as a chemoprotectant and an immunomodulator. NOV-002 is also in Phase 2 development for chemotherapy-resistant ovarian cancer and early-stage breast cancer, and is in addition being developed for acute radiation injury. NOV-205 acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties. NOV-205 is in Phase 1b development for chronic hepatitis C non-responders. Both compounds have completed clinical trials in humans and have been approved for use in the Russian Federation where they were originally developed.

Company: OMRIX Biopharmaceuticals, Inc.
Ticker Symbol & Exchange: NASDAQ: OMRI
Investor Relations Contact: Francesca DeMartino, 212-887-6510
Web: http://www.omrix.com
Date of Presentation: May 14, 2007; 9:45 AM (Local Time)
OMRIX is a profitable, fully-integrated biopharmaceutical company developing and marketing protein-based biosurgery and passive immunotherapy products. We utilize our proprietary protein purification technology and manufacturing know-how to develop products within our diversified and synergistic business platforms and establish a presence in growing and under-penetrated markets. Our biosurgery product line includes products and product candidates, such as liquid fibrin sealants and thrombin products, used for the control of bleeding, or hemostasis, and other surgical applications. Our passive immunotherapy product line includes antibody-rich products and product candidates for the treatment of immune deficiencies, infectious diseases and potential biodefense applications.

Company: Orexo AB
Ticker Symbol & Exchange: ORX (SSE)
Investor Relations Contact: Mr Claes Wenthzel, Executive Vice President & CEO, 46 18 780 88 00
Web: http://www.orexo.com
Date of Presentation: 15-May-07
Orexo AB is a pharmaceutical company developing new pharmaceutical drugs within areas currently subject to considerable unmet medical needs. Orexo applies its broad expertise in medicine and pharmaceuticals to the further development of existing pharmaceutical substances. By combining well-documented compounds with its own patented drug delivery methods and its unique expertise in "dry formulations" (for example, tablets), Orexo is able to develop new patented pharmaceuticals.

Orexo has grown into an organization with 67 full-time employees, most of whom are active in research and development, clinical development and pharmaceutical registration. At present, the company has two products on the market, three products in late clinical development phase - one of which has been out-licensed in the US, Europe and Japan and submitted for registration in Europe - and two projects in pharmaceutical formulation phase. Orexo has adopted an active intellectual property rights strategy and has, since its inception, built up an extensive patent portfolio to protect its products and technologies.

Company: PAION AG
Ticker Symbol & Exchange: PA8, Frankfurt Stock Exchange
Investor Relations Contact: Dr. Peer Nils Schroeder, 49-241-4453-152
Web: http://www.paion.de
Date of Presentation: 14-May-07
PAION, a biopharmaceutical company based in Aachen, Germany, aims to become a leader in developing and commercialising innovative drugs for the treatment of stroke and other thrombotic diseases for which there is a substantial unmet medical need. PAION intends to build an integrated drug portfolio by exploiting its expertise in identifying compounds, licensing or otherwise acquiring them and advancing them through the clinical development and regulatory approval process. Results for the Phase III study of PAION's lead product Desmoteplase will be presented 1 June 2007. In 2006, PAION employed on average 77 people.

Company: Pipex Pharmaceuticals, Inc.
Ticker Symbol & Exchange: PPXP (OTCBB)
Investor Relations Contact: Thomas Redington, 203-222-7399
Web: http://www.pipexpharma.com
Date of Presentation: 5/15/2007
Pipex Pharmaceuticals, Inc. is a specialty pharmaceutical company that is developing proprietary, late-stage drug candidates for the treatment of neurologic and fibrotic diseases. Pipex's lead product, COPREXA™ (oral tetrathiomolybdate) has completed pivotal clinical trials for an orphan genetic disease, known as neurologic Wilson's disease and has also completed phase II clinical trials for Idiopathic Pulmonary Fibrosis (IPF), a deadly lung disease.

Pipex is also developing TRIMESTA™ (oral estriol) for the treatment of multiple sclerosis which has completed a phase II clinical trial. For further information, please visit, www.pipexpharma.com.

Company: Prana Biotechnology Ltd.
Ticker Symbol & Exchange: PRAN: NASDAQ / PBT: ASX (Australia)
Investor Relations Contact: Kathy Price, 646-284-9430
Web: http://www.pranabio.com
Date of Presentation: 15-May-07
Prana Biotechnology Ltd. is a biopharmaceutical company focused on the research and development of treatments for Alzheimer's disease and other age-related neurodegenerative disorders. Prana's discoveries, emerging out of Massachusetts General Hospital at Harvard University and the University of Melbourne in Australia, have lead to the development of MPAC's (Metal Protein Attenuating Compounds). MPAC's have shown great promise to treat a variety of neurodegenerative disorders. Clinical efficacy (phase 2) has earlier been demonstrated in a ‘proof of principle' MPAC (PBT1) for Alzheimer's disease. Prana's lead proprietary molecule, PBT2, is currently in Phase IIa testing for Alzheimer's disease.

Company: ProMetic Life Sciences Inc.
Ticker Symbol & Exchange: PLI (TSX)
Investor Relations Contact: Lippert/Heilshorn & Associates, Inc, Lisa Lindberg, (212) 838-3777
Web: http://www.prometic.com
Date of Presentation: May 15, 2007 - 3:15pm

ProMetic Life Sciences Inc. is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand(TM) enabling technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of inflammation and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montréal, Canada, ProMetic has R&D and manufacturing facilities in the UK and business development activities in the US, Europe, Asia and MENA countries (Middle East and North Africa).

Company: Protherics PLC
Ticker Symbol & Exchange: LSE: PTI, NASDAQ: PTIL
Investor Relations Contact: Nick Staples, 44 (0)20 7246 9950 or 44 (0)7919 480 510
Web: http://www.protherics.com
Date of Presentation: 10.50am Tuesday 15 May
Protherics PLC is a leading biopharmaceutical company focused on the development, manufacture and marketing of specialised products for critical care and cancer.

Protherics has developed and manufactures two biologics for critical care which are FDA approved and currently sold in the US: CroFab™, a pit viper antivenom and DigiFab™, a digoxin antidote. The Company's strategy is to use the revenues generated from its marketed and out-licensed products to help fund the advancement of its broad, late stage pipeline.

Protherics has two major development opportunities in its critical care portfolio. CytoFab™ is being developed by AstraZeneca for the treatment of severe sepsis and Digoxin Immune Fabs for the treatment of pre-eclampsia. Protherics also has a pipeline of four novel cancer products in clinical development.

With headquarters in London, the Company has approximately 260 employees in the UK, US and Australia. For further information please visit www.protherics.com

Company: Starpharma Holdings Limited
Ticker Symbol & Exchange: ASX:SPL, OTCQX: SPHRY
Investor Relations Contact: Jennifer K. Zimmons, Ph.D.; 212-838-1444 or Dr Jackie Fairley, CEO; 61 3 8532 2704, 61 407 716 887 (Cell)
Web: http://www.starpharma.com
Date of Presentation: Tuesday May 15, 2007 - 9:45am
Starpharma is pioneering the development of dendrimer nanotechnology products for pharmaceutical, life science, and other applications.

Lead product, VivaGel™, is a vaginal microbicide designed to prevent the transmission of Sexually Transmitted Infections (specifically HIV and genital herpes). Currently in human clinical trials, VivaGel™ has received US FDA Fast Track status and more than USD 20M in non-dilutive support from the NIH. VivaGel™ addresses multi-billion dollar markets aimed at preventing sexually transmitted infections. The product has also shown activity as a contraceptive and the active ingredient has potential application as a condom coating agent.

Through the 2006 acquisition of US-based Dendritic Nanotechnologies, Starpharma has expanded its product pipeline to include drug delivery, siRNA transfection and industrial chemical applications. Through DNT the company has royalty-bearing relationships with Dade Behring, Qiagen, Sigma, Aldrich and EMD Biosciences.

With an active American Depositary Receipts (ADR) program (OTCQX:SPHRY) in place, Dow Chemical (NASDQ:DOW) as lead shareholder, and US offices, Starpharma is actively embracing the US market. Currently more than 20% of Starpharma's shares are held by US investors, with DOW holding 8.6%.

Company: Tercica, Inc.
Ticker Symbol & Exchange: Nasdaq: TRCA
Investor Relations Contact: Fredrik Wiklund, 650-624-4992
Web: http://www.tercica.com
Date of Presentation: 5/14/07 at 9:00 a.m. local time
Tercica is a biopharmaceutical company committed to improving endocrine health by partnering with the endocrine community to develop and commercialize new therapeutics for short stature and other metabolic disorders. For further information on Tercica, please visit www.tercica.com.

Company: UTEK Corporation
Ticker Symbol & Exchange: AMEX: UTK and LSE-AIM: UTK
Investor Relations Contact: Steve Liebmann or Simon Bloomfield, 44 (0) 20-7367-8883
Web: http://www.utekcorp.com
Date of Presentation: Monday, May 14, 2007
UTEK® is a specialty finance company focused on technology transfer. UTEK's services enable companies to rapidly acquire innovative technologies from universities and research laboratories worldwide in exchange for their equity securities. This unique process is called U2B®. In addition, UTEK offers companies the tools to search, and analyze intellectual properties. UTEK is a business development company with operations in the United States, United Kingdom and Israel.

Company: ViroPharma Incorporated
Ticker Symbol & Exchange: Nasdaq: VPHM
Investor Relations Contact: Will Roberts, 610-321-6288
Web: http://www.viropharma.com
Date of Presentation: 5/14/2007
ViroPharma Incorporated is committed to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin® approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/docs/Vancocin_pi_2007.htm ). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C virus (HCV).

Company: XYTIS
Investor Relations Contact: Vincent F. Simmon, Chairman, President & CEO, 949 226 1118
Web: http://www.xytis.com
Date of Presentation: May 14th 2007 at 9:45AM
Xytis is a CNS small molecule private company formed in 2005 by the merger of Xytis Pharmaceuticals Ltd. and Remergent Inc. Current investors are Atlas Venture, Sanderling, CDC Entreprises, and Ventech. Xytis pipeline includes two compounds in the clinic. XY2405, an inhibitor of Bradykinin B2 receptor, is in PhII trial for Traumatic Brain Injury. XY2401, currently in PhIb, is an anti-psychotic agent that was shown to improve cognitive performance and revealed anxiolytic and anti-depressive activity in animal models. In addition, Xytis has a rich portfolio of preclinical compounds that are highly selective positive allosteric modulators of nicotinic Acetylcholine and GABAA receptors being readied for IND filing.

Company: ZIOPHARM Oncology, Inc.
Ticker Symbol & Exchange: ZIOP: NASDAQ
Investor Relations Contact: Suzanne McKenna, 646-214-0703
Web: http://www.ziopharm.com
Date of Presentation: 15-May-07
ZIOPHARM Oncology is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment.